ArticleJournal of thoracic disease2026
Evolution of proton pump inhibitor research in reflux esophagitis: a Web of Science-based global bibliometric assessment [1990-2026].
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Reflux esophagitis remains a prevalent acid-related disorder with an increasing global burden, yet the growing challenges of refractory disease and the transition toward newer acid-suppressing agents highlight critical knowledge gaps. This study aimed to analyze the global research trends and identify emerging hotspots in proton pump inhibitors (PPIs) treatment for reflux esophagitis through a Web of Science-based bibliometric analysis [1990-2026]. Methods: A systematic search was conducted in the Web of Science Core Collection (WoSCC) on June 18, 2026, using MeSH-derived terms. Only English-language original research articles were included. Two independent researchers manually screened all records for relevance. The analysis was performed using VOSviewer, CiteSpace, and the "bibliometrix" package of R. Results: A total of 338 articles were included. Publications showed an overall upward trend with an annual growth rate of 2%. Japan emerged as the leading country (111 publications), followed by the United States [59] and China [38]. The Conclusions: Three distinct research phases were identified in PPI treatment for reflux esophagitis. Current research insufficiently addresses the long-term impact of PPIs on gut microbiome and the comparative effectiveness of emerging potassium-competitive acid blockers (P-CABs). Future research should prioritize pharmacogenetic optimization, real-world evidence generation for novel therapeutic agents, and enhanced international collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.